Top

Published in:

Open Access 01-12-2022 | Myotonic Dystrophy | Research

Quality of life and subjective symptom impact in Japanese patients with myotonic dystrophy type 1

Authors: Haruo Fujino, Toshio Saito, Masanori P. Takahashi, Hiroto Takada, Takahiro Nakayama, Osamu Imura, Tsuyoshi Matsumura

Published in: BMC Neurology | Issue 1/2022

Abstract

Background

Although functional impairment in patients with myotonic dystrophy is an important determinant of the quality of life (QoL), patients’ subjective evaluation of their symptoms may also affect their QoL. The aim of this study was to investigate the association between subjective symptom impact and the QoL of patients with myotonic dystrophy, after controlling for functional impairment.

Methods

Eligible patients with myotonic dystrophy type 1 (DM1) were recruited from four hospitals in Japan. The subjective symptom impact of four symptoms (muscle weakness, fatigue, pain, and myotonia) and overall QoL were evaluated using the Individualized Neuromuscular Quality of Life (INQoL) questionnaire. Functional impairment was assessed using the modified Rankin Scale.

Results

Seventy-seven patients with DM1 were included in this study. Overall QoL was significantly associated with subjective symptom impact of muscular weakness, fatigue, pain, myotonia, swallowing difficulty, and droopy eyelids. In the regression models, disease duration (beta = 0.11) and moderate to severe functional impairment (beta = 0.33) explained a significant part of the overall QoL. Furthermore, muscular weakness, fatigue, and myotonia significantly explained additional variance of the overall QoL (beta = 0.17–0.43).

Conclusions

Subjective symptom impact and functional impairment are independent features influencing the QoL of Japanese patients with DM1.

Turner C, Hilton-Jones D. The myotonic dystrophies: diagnosis and management. J Neurol Neurosurg Psychiatry. 2010;81(4):358–67. https://doi.org/10.1136/jnnp.2008.158261.CrossRefPubMed

Bann CM, Abresch RT, Biesecker B, Conway KC, Heatwole C, Peay H, et al. Measuring quality of life in muscular dystrophy. Neurology. 2015;84(10):1034–42. https://doi.org/10.1212/WNL.0000000000001336.CrossRefPubMedPubMedCentral

Burns TM, Graham CD, Rose MR, Simmons Z. Quality of life and measures of quality of life in patients with neuromuscular disorders. Muscle Nerve. 2012;46(1):9–25. https://doi.org/10.1002/mus.23245.CrossRefPubMed

Graham CD, Rose MR, Grunfeld EA, Kyle SD, Weinman J. A systematic review of quality of life in adults with muscle disease. J Neurol. 2011;258(9):1581–92. https://doi.org/10.1007/s00415-011-6062-5.CrossRefPubMed

Bos I, Wynia K, Almansa J, Drost G, Kremer B, Kuks J. The prevalence and severity of disease-related disabilities and their impact on quality of life in neuromuscular diseases. Disabil Rehabil. 2019;41(14):1676–81. https://doi.org/10.1080/09638288.2018.1446188.CrossRefPubMed

Gagnon C, Mathieu J, Jean S, Laberge L, Perron M, Veillette S, et al. Predictors of disrupted social participation in myotonic dystrophy type 1. Arch Phys Med Rehabil. 2008;89(7):1246–55. https://doi.org/10.1016/j.apmr.2007.10.049.CrossRefPubMed

Graham CD, Weinman J, Sadjadi R, Chalder T, Petty R, Hanna MG, et al. A multicentre postal survey investigating the contribution of illness perceptions, coping and optimism to quality of life and mood in adults with muscle disease. Clin Rehabil. 2014;28(5):508–19. https://doi.org/10.1177/0269215513511340.CrossRefPubMed

Natterlund B, Ahlstrom G. Activities of daily living and quality of life in persons with muscular dystrophy. J Rehabil Med. 2001;33(5):206–11.CrossRefPubMed

Albrecht GL, Devlieger PJ. The disability paradox: high quality of life against all odds. Soc Sci Med. 1999;48(8):977–88. https://doi.org/10.1016/s0277-9536(98)00411-0.CrossRefPubMed

10.

Schwartz CE, Sprangers MAG. Methodological approaches for assessing response shift in longitudinal health-related quality-of-life research. Soc Sci Med. 1999;48(11):1531–48. https://doi.org/10.1016/s0277-9536(99)00047-7.CrossRefPubMed

11.

Peric S, Vujnic M, Dobricic V, Marjanovic A, Basta I, Novakovic I, et al. Five-year study of quality of life in myotonic dystrophy. Acta Neurol Scand. 2016;134(5):346–51. https://doi.org/10.1111/ane.12549.CrossRefPubMed

12.

Ware JE, Gandek B. Overview of the SF-36 health survey and the international quality of life assessment (IQOLA) project. J Clin Epidemiol. 1998;51(11):903–12. https://doi.org/10.1016/s0895-4356(98)00081-x.CrossRefPubMed

13.

Symonds T, Campbell P, Randall JA. A review of muscle- and performance-based assessment instruments in DM1. Muscle Nerve. 2017;56(1):78–85. https://doi.org/10.1002/mus.25468.CrossRefPubMed

14.

Symonds T, Randall JA, Campbell P. Review of patient-reported outcome measures for use in myotonic dystrophy type 1 patients. Muscle Nerve. 2017;56(1):86–92. https://doi.org/10.1002/mus.25469.CrossRefPubMed

15.

Baldanzi S, Bevilacqua F, Lorio R, Volpi L, Simoncini C, Petrucci A, et al. Disease awareness in myotonic dystrophy type 1: an observational cross-sectional study. Orphanet J Rare Dis. 2016;11:34. https://doi.org/10.1186/s13023-016-0417-z.CrossRefPubMedPubMedCentral

16.

Ahlstrom G, Sjoden PO. Coping with illness-related problems and quality of life in adult individuals with muscular dystrophy. J Psychosom Res. 1996;41(4):365–76.CrossRefPubMed

17.

Geirdal AO, Lund-Petersen I, Heiberg A. Understanding the experience of myotonic dystrophy. Mixed method study. J Genet Couns. 2015;24(1):169–78. https://doi.org/10.1007/s10897-014-9752-1.CrossRefPubMedPubMedCentral

18.

Fujino H, Saito T, Takahashi MP, Takada H, Nakayama T, Ogata K, et al. Validation of the individualized neuromuscular quality of life in Japanese patients with myotonic dystrophy. Muscle Nerve. 2018. https://doi.org/10.1002/mus.26071.

19.

Vincent KA, Carr AJ, Walburn J, Scott DL, Rose MR. Construction and validation of a quality of life questionnaire for neuromuscular disease (INQoL). Neurology. 2007;68(13):1051–7. https://doi.org/10.1212/01.wnl.0000257819.47628.41.CrossRefPubMed

20.

van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988;19(5):604–7.CrossRefPubMed

21.

Mori I, Fujino H, Matsumura T, Takada H, Ogata K, Nakamori M, et al. The myotonic dystrophy health index: Japanese adaption and validity testing. Muscle Nerve. 2019;59(5):577–82. https://doi.org/10.1002/mus.26422.CrossRefPubMed

22.

Seesing FM, van Vught LE, Rose MR, Drost G, van Engelen BG, van der Wilt GJ. The individualized neuromuscular quality of life questionnaire: cultural translation and psychometric validation for the Dutch population. Muscle Nerve. 2015;51(4):496–500. https://doi.org/10.1002/mus.24337.CrossRefPubMed

23.

Landfeldt E, Nikolenko N, Jimenez-Moreno C, Cumming S, Monckton DG, Gorman G, et al. Disease burden of myotonic dystrophy type 1. J Neurol. 2019;266(4):998–1006. https://doi.org/10.1007/s00415-019-09228-w.CrossRefPubMedPubMedCentral

24.

Sansone VA, Ricci C, Montanari M, Apolone G, Rose M, Meola G. Measuring quality of life impairment in skeletal muscle channelopathies. Eur J Neurol. 2012;19(11):1470–6. https://doi.org/10.1111/j.1468-1331.2012.03751.x.CrossRefPubMedPubMedCentral

25.

Laberge L, Mathieu J, Auclair J, Gagnon E, Noreau L, Gagnon C. Clinical, psychosocial, and central correlates of quality of life in myotonic dystrophy type 1 patients. Eur Neurol. 2013;70(5–6):308–15. https://doi.org/10.1159/000353991.CrossRefPubMed

26.

Rakocevic-Stojanovic V, Peric S, Madzarevic R, Dobricic V, Ralic V, Ilic V, et al. Significant impact of behavioral and cognitive impairment on quality of life in patients with myotonic dystrophy type 1. Clin Neurol Neurosurg. 2014;126:76–81. https://doi.org/10.1016/j.clineuro.2014.08.021.CrossRefPubMed

27.

Sansone VA, Panzeri M, Montanari M, Apolone G, Gandossini S, Rose MR, et al. Italian validation of INQoL, a quality of life questionnaire for adults with muscle diseases. Eur J Neurol. 2010;17(9):1178–87. https://doi.org/10.1111/j.1468-1331.2010.02992.x.CrossRefPubMed

28.

Heatwole C, Bode R, Johnson N, Quinn C, Martens W, McDermott MP, et al. Patient-reported impact of symptoms in myotonic dystrophy type 1 (PRISM-1). Neurology. 2012;79(4):348–57. https://doi.org/10.1212/WNL.0b013e318260cbe6.CrossRefPubMedPubMedCentral

29.

Cumming SA, Jimenez-Moreno C, Okkersen K, Wenninger S, Daidj F, Hogarth F, et al. Genetic determinants of disease severity in the myotonic dystrophy type 1 OPTIMISTIC cohort. Neurology. 2019;93(10):e995–e1009. https://doi.org/10.1212/WNL.0000000000008056.CrossRefPubMedPubMedCentral

30.

Natterlund B, Gunnarsson LG, Ahlstrom G. Disability, coping and quality of life in individuals with muscular dystrophy: a prospective study over five years. Disabil Rehabil. 2000;22(17):776–85.CrossRefPubMed

31.

Peric S, Heatwole C, Durovic E, Kacar A, Nikolic A, Basta I, et al. Prospective measurement of quality of life in myotonic dystrophy type 1. Acta Neurol Scand. 2017;136(6):694–7. https://doi.org/10.1111/ane.12788.CrossRefPubMed

32.

Sprangers MA, Schwartz CE. Integrating response shift into health-related quality of life research: a theoretical model. Soc Sci Med. 1999;48(11):1507–15.CrossRefPubMed

33.

Rose MR, Sadjadi R, Weinman J, Akhtar T, Pandya S, Kissel JT, et al. Role of disease severity, illness perceptions, and mood on quality of life in muscle disease. Muscle Nerve. 2012;46(3):351–9. https://doi.org/10.1002/mus.23320.CrossRefPubMed

34.

Walklet E, Muse K, Meyrick J, Moss T. Do psychosocial interventions improve quality of life and wellbeing in adults with neuromuscular disorders? A systematic review and narrative synthesis. J Neuromuscul Dis. 2016;3(3):347–62. https://doi.org/10.3233/JND-160155.CrossRefPubMedPubMedCentral

35.

Gagnon C, Gallais B, Laberge L. Myotonic dystrophy type 1: reasons to be OPTIMISTIC. Lancet Neurol. 2018;17(8):652–3. https://doi.org/10.1016/S1474-4422(18)30240-0.CrossRefPubMed

36.

Gagnon C, Tremblay M, CoTe I, Heatwole C. French translation and cross-cultural adaptation of the Myotonic dystrophy health index. Muscle Nerve. 2018;57(4):686–9. https://doi.org/10.1002/mus.25994.CrossRefPubMed

37.

Okkersen K, Jimenez-Moreno C, Wenninger S, Daidj F, Glennon J, Cumming S, et al. Cognitive behavioural therapy with optional graded exercise therapy in patients with severe fatigue with myotonic dystrophy type 1: a multicentre, single-blind, randomised trial. Lancet Neurol. 2018;17(8):671–80. https://doi.org/10.1016/S1474-4422(18)30203-5.CrossRefPubMed

38.

Heatwole C, Bode R, Johnson N, Dekdebrun J, Dilek N, Heatwole M, et al. Myotonic dystrophy health index: initial evaluation of a disease-specific outcome measure. Muscle Nerve. 2014;49(6):906–14. https://doi.org/10.1002/mus.24097.CrossRefPubMedPubMedCentral

39.

Heatwole C, Bode R, Johnson NE, Dekdebrun J, Dilek N, Eichinger K, et al. Myotonic dystrophy health index: correlations with clinical tests and patient function. Muscle Nerve. 2016;53(2):183–90. https://doi.org/10.1002/mus.24725.CrossRefPubMed

40.

Sansone VA, Lizio A, Greco L, Gragnano G, Zanolini A, Gualandris M, et al. The Myotonic dystrophy health index: Italian validation of a disease-specific outcome measure. Neuromuscul Disord. 2017;27(11):1047–53. https://doi.org/10.1016/j.nmd.2017.07.004.CrossRefPubMed

41.

Fujino H, Shingaki H, Suwazono S, Ueda Y, Wada C, Nakayama T, et al. Cognitive impairment and quality of life in patients with myotonic dystrophy type 1. Muscle Nerve. 2018;57(5):742–8. https://doi.org/10.1002/mus.26022.CrossRefPubMed

42.

Peric S, Rakocevic Stojanovic V, Mandic Stojmenovic G, Ilic V, Kovacevic M, Parojcic A, et al. Clusters of cognitive impairment among different phenotypes of myotonic dystrophy type 1 and type 2. Neurol Sci. 2017;38(3):415–23. https://doi.org/10.1007/s10072-016-2778-4.CrossRefPubMed

43.

Dany A, Barbe C, Rapin A, Reveillere C, Hardouin JB, Morrone I, et al. Construction of a quality of life questionnaire for slowly progressive neuromuscular disease. Qual Life Res. 2015;24(11):2615–23. https://doi.org/10.1007/s11136-015-1013-8.CrossRefPubMed

44.

Dany A, Rapin A, Lavrard B, Saout V, Reveillere C, Bassez G, et al. The quality of life in genetic neuromuscular disease questionnaire: Rasch validation of the French version. Muscle Nerve. 2017;56(6):1085–91. https://doi.org/10.1002/mus.25598.CrossRefPubMed

Title: Quality of life and subjective symptom impact in Japanese patients with myotonic dystrophy type 1
Authors: Haruo Fujino
Toshio Saito
Masanori P. Takahashi
Hiroto Takada
Takahiro Nakayama
Osamu Imura
Tsuyoshi Matsumura
Publication date: 01-12-2022
Publisher: BioMed Central
Keywords: Myotonic Dystrophy
Myotonia
Myotonic Dystrophy
Myotonia
Fatigue
Published in: BMC Neurology / Issue 1/2022
Electronic ISSN: 1471-2377
DOI: https://doi.org/10.1186/s12883-022-02581-w

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Quality of life and subjective symptom impact in Japanese patients with myotonic dystrophy type 1

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2022

Longitudinal extensive transverse myelitis after chemoradiation therapy with durvalumab, a rare complication: case report

Hypoglossal nerve palsy after SARS-CoV-2 vaccination – report of two cases

Cardiac dysfunction and high-sensitive C-reactive protein are associated with troponin T elevation in ischemic stroke: insights from the SICFAIL study

Validation of a novel computerized cognitive function test for the rapid detection of mild cognitive impairment

Bilateral paralysis of peroneal nerve after COVID-19 disease: a case report

Efficacy and safety of butylphthalide in secondary prevention of stroke: study protocol for a multicenter, real world trial based on Internet